By Counterforce Health Team in Strimvelis (autologous CD34+ ADA-SCID gene therapy) —

Getting Strimvelis Gene Therapy Covered by Blue Cross Blue Shield in California: Complete Coding, Appeals, and Authorization Guide

Quick Answer: Getting Strimvelis Covered by Blue Cross Blue Shield in California

Blue Cross Blue Shield plans in California require prior authorization for Strimvelis (autologous CD34+ gene therapy for ADA-SCID), administered only at SR-TIGET in Milan, Italy. Use ICD-10 code D81.31 (severe combined immunodeficiency due to adenosine deaminase deficiency) and HCPCS code J3590 (unclassified biologics). If denied, California's Independent Medical Review (IMR) has a 68.6% success rate for overturning Blue Cross denials. Start with your provider's prior authorization portal and gather genetic testing, enzyme assays, and failed treatment documentation.

Table of Contents

  1. Coding Basics: Medical vs. Pharmacy Benefit Paths
  2. ICD-10 Mapping and Documentation Requirements
  3. Product Coding: HCPCS, J-Codes, and NDC Numbers
  4. Clean Request Anatomy: Building Your Prior Authorization
  5. Frequent Pitfalls and How to Avoid Them
  6. Verification Steps with Blue Cross Blue Shield
  7. Appeals Process: From Internal Review to California IMR
  8. Quick Audit Checklist
  9. FAQ: Common Questions About Strimvelis Coverage

Coding Basics: Medical vs. Pharmacy Benefit Paths

Strimvelis falls under the medical benefit for all Blue Cross Blue Shield plans because it requires specialized administration at SR-TIGET in Milan, Italy. Unlike standard pharmacy-dispensed medications, this gene therapy involves complex manufacturing and immediate infusion.

Benefit Path Coverage Details Authorization Route
Medical Benefit Primary pathway; covers hospital/outpatient infusion and international care coordination Prior auth via provider portal or transplant network
Pharmacy Benefit Not applicable for Strimvelis due to on-site manufacturing requirements N/A

The medical benefit path means your claim will be processed through Blue Cross Blue Shield's specialty medical services, not their pharmacy formulary system. This typically involves more comprehensive review but also allows for medical necessity appeals.

Note: Blue Cross Blue Shield's Global Core program provides limited international coverage, but comprehensive treatment like Strimvelis may require additional travel insurance or Global Solutions coverage.

ICD-10 Mapping and Documentation Requirements

The primary diagnosis code for ADA-SCID is D81.31 (Severe combined immunodeficiency due to adenosine deaminase deficiency). This falls under the broader category D81 (Combined immunodeficiencies).

Required Documentation for D81.31

Blue Cross Blue Shield requires specific clinical evidence to support this diagnosis:

  • ADA enzyme activity less than 1% of normal in red blood cells or lymphocytes
  • Genetic testing showing biallelic pathogenic ADA gene variants
  • Flow cytometry demonstrating absent or severely reduced T, B, and NK cells
  • Clinical history of recurrent infections, failure to thrive, and immune dysfunction
  • Newborn screening results (TREC levels) if available

Supporting ICD-10 Codes

You may need additional codes depending on complications:

  • Z87.891 - Personal history of nicotine dependence (if relevant for family history)
  • Z94.81 - Bone marrow transplant status (if previous HSCT attempted)
  • T86.00 - Unspecified complication of bone marrow transplant (if applicable)

Product Coding: HCPCS, J-Codes, and NDC Numbers

Since Strimvelis lacks FDA approval and a permanent U.S. HCPCS code, use the unclassified biologics code:

Primary Billing Code

  • J3590 - Unclassified biologics (most common for physician/outpatient settings)
  • Alternative: C9399 - Unclassified drugs/biologics for hospital outpatient departments

Units and Billing Details

  • Units: 1 unit per complete treatment (one-time administration)
  • NDC: No standard U.S. NDC number; use patient-specific code from SR-TIGET packaging if available
  • Description: "Strimvelis autologous CD34+ gene therapy for ADA-SCID"
Tip: Include detailed description in claims to avoid automatic denials for unclassified codes.

Clean Request Anatomy: Building Your Prior Authorization

A successful prior authorization for Strimvelis requires comprehensive documentation. Here's what Blue Cross Blue Shield typically requires:

Essential Components

  1. Patient Demographics and Insurance Information
    • Member ID, group number, policy effective dates
    • Primary and secondary insurance details
  2. Clinical Documentation
    • Specialist letter from pediatric immunologist or geneticist
    • Genetic testing reports showing ADA gene mutations
    • Enzyme assay results (ADA activity <1% normal)
    • Immunological workup (T-cell counts, antibody levels)
  3. Treatment History
    • Documentation of PEG-ADA enzyme replacement therapy trials
    • Reasons for treatment failure or intolerance
    • Hematopoietic stem cell transplant evaluation (donor search results)
  4. SR-TIGET Coordination
    • Acceptance letter from SR-TIGET in Milan
    • Treatment protocol and timeline
    • Cost estimate including travel and accommodation

When working with complex international treatments like Strimvelis, Counterforce Health helps patients and clinicians navigate insurance denials by creating targeted, evidence-backed appeals that address specific payer requirements and increase approval chances.

Frequent Pitfalls and How to Avoid Them

Common Mistakes That Lead to Denials

  1. Incomplete Genetic Documentation
    • Problem: Submitting only clinical symptoms without genetic confirmation
    • Solution: Include comprehensive genetic testing showing biallelic ADA mutations
  2. Missing Treatment History
    • Problem: No documentation of failed conventional therapies
    • Solution: Provide detailed records of PEG-ADA trials and HSCT evaluation
  3. Incorrect Coding
    • Problem: Using D81.3 (unspecified) instead of D81.31 (ADA-specific)
    • Solution: Use the most specific ICD-10 code available
  4. Inadequate Medical Necessity Letter
    • Problem: Generic letters without ADA-SCID specific clinical rationale
    • Solution: Include peer-reviewed literature and EMA approval data

Unit Conversion and Billing Errors

Since Strimvelis is a one-time treatment, avoid these common billing mistakes:

  • Don't calculate units based on patient weight or BSA
  • Don't submit multiple units for the same treatment episode
  • Don't use standard oncology drug billing practices

Verification Steps with Blue Cross Blue Shield

Before submitting your prior authorization, verify these details with Blue Cross Blue Shield:

Pre-Submission Checklist

  1. Confirm Coverage
    • Call member services to verify active coverage
    • Check if international treatment benefits apply
    • Confirm prior authorization requirements
  2. Provider Portal Access
    • Ensure your clinic has active provider portal access
    • Download current PA forms for specialty biologics
    • Verify submission deadlines and required attachments
  3. Network Status
    • Confirm SR-TIGET's status (likely out-of-network)
    • Check if Global Core or international benefits apply
    • Understand out-of-pocket costs and deductibles

Contact Information for Verification

  • Member Services: Number on back of insurance card
  • Provider Services: Available through Blue Cross Blue Shield provider portal
  • Specialty Pharmacy: For complex biologics questions

Appeals Process: From Internal Review to California IMR

If Blue Cross Blue Shield denies coverage for Strimvelis, California offers robust appeal rights through the Department of Managed Health Care (DMHC).

Internal Appeal (First Level)

Timeline: File within 180 days of denial Process: Submit enhanced documentation addressing specific denial reasons Duration: 30 days for standard review, 72 hours for expedited

Independent Medical Review (IMR)

California's IMR system has shown strong success rates for rare disease treatments:

  • Blue Cross/Anthem specific success rate: 68.6% of medical necessity denials overturned in 2023
  • Overall IMR success rate: 61% of all cases result in denial reversals
  • Timeline: 45 days for standard IMR, 72 hours for expedited cases

How to File an IMR

  1. Eligibility: Must complete internal appeal first (or wait 30 days)
  2. Application: File through DMHC website or call 888-466-2219
  3. Cost: No fee to patients; insurers pay for the review
  4. Decision: Binding on the insurance company
From our advocates: In complex gene therapy cases, we've seen success when families include economic analyses showing lifetime care costs versus one-time treatment expenses. While outcomes vary, thorough documentation of medical necessity often strengthens IMR cases significantly.

For patients navigating these complex appeals, Counterforce Health specializes in turning insurance denials into successful approvals by crafting point-by-point rebuttals that align with each payer's specific requirements and California's regulatory framework.

Quick Audit Checklist

Before submitting your Strimvelis prior authorization, review this checklist:

Documentation Review

  • ICD-10 code D81.31 confirmed with genetic testing
  • HCPCS J3590 with detailed description included
  • ADA enzyme activity <1% documented
  • PEG-ADA failure or contraindication explained
  • HSCT donor search completed (no suitable donor found)
  • SR-TIGET acceptance letter attached

Submission Details

  • Correct Blue Cross Blue Shield plan identified
  • Provider portal submission or correct fax number used
  • All required forms completed and signed
  • Medical necessity letter includes peer-reviewed references
  • Cost estimate and travel plan included
  • Expedited review requested if clinically urgent

Follow-Up Planning

  • Submission confirmation received
  • Calendar reminders set for decision timeline
  • Appeal strategy prepared if denied
  • DMHC contact information saved for potential IMR

FAQ: Common Questions About Strimvelis Coverage

Q: How long does Blue Cross Blue Shield prior authorization take in California? A: Standard review takes up to 30 days. Expedited review (if medically urgent) takes 72 hours. International coordination may extend timelines.

Q: What if Strimvelis is considered experimental by Blue Cross Blue Shield? A: Document EMA approval status and published efficacy data. California's IMR system often favors patients when treatments have regulatory approval in other developed countries.

Q: Can I request an expedited appeal if my child's condition is worsening? A: Yes. Provide documentation from your specialist that delay in treatment poses immediate health risks. Both internal appeals and IMR offer expedited tracks.

Q: Does step therapy apply to Strimvelis? A: Typically yes. You'll need to document failed trials of PEG-ADA enzyme replacement therapy and inability to proceed with HSCT due to lack of suitable donor.

Q: What are my out-of-pocket costs for international treatment? A: This varies by plan. Standard Blue Cross Blue Shield plans may have higher out-of-network costs. Global Solutions or supplemental travel insurance may reduce expenses.

Q: How do I find SR-TIGET's network status with my Blue Cross Blue Shield plan? A: Contact member services directly, as SR-TIGET is likely not in standard provider directories. Ask specifically about international Centers of Excellence coverage.

Q: What happens if Blue Cross Blue Shield approves treatment but denies travel costs? A: Travel, accommodation, and companion expenses are typically separate from medical coverage. Consider manufacturer patient assistance programs or medical travel insurance.

Q: Can I appeal to California regulators if IMR denies my case? A: IMR decisions are generally final and binding. However, you can file complaints about process violations with DMHC or pursue legal options in extreme cases.

Sources & Further Reading

Disclaimer: This guide provides general information about insurance coverage and appeals processes. It is not medical advice or a guarantee of coverage approval. Always consult with your healthcare provider and insurance company for specific guidance about your situation. Coverage policies and requirements may change; verify current information with official sources.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.